• Vericel Corporation recently received U.S. Food and Drug Administration approval to begin commercial manufacturing of its MACI cartilage repair therapy at a new cell therapy facility in Burlington, Massachusetts, enabling production to start in the second quarter of 2026.
• This expansion of MACI manufacturing capacity is important because it supports higher volumes for knee cartilage repair and lays groundwork for potential international commercialization.
• Next, we’ll explore how FDA approval of MACI manufacturing at the Burlington facility could reshape Vericel’s longer-term investment narrative.

Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.

Vericel Investment Narrative Recap

To own Vericel, you need to believe in sustained adoption of its cell therapies, led by MACI, and the company’s ability to scale profitably despite a concentrated product portfolio and rising operating costs. FDA approval to manufacture MACI in Burlington supports the near term capacity ramp that underpins this story, but it does not remove key risks such as potential payer pressure on pricing or execution risk as the new facility comes online.

The recent FDA decision on Burlington ties directly to Vericel’s previously outlined operational initiatives, where the new manufacturing facility was expected to support MACI production starting in 2026. That approval now locks in a clearer path for higher MACI volumes to support the company’s 2026 revenue guidance of US$316 million to US$326 million, while also intersecting with Vericel’s ambitions for international MACI commercialization as a longer term growth driver.

However, investors should also be aware that if rising MACI manufacturing and commercial costs are not matched by revenue growth and stable reimbursement...

Vericel's narrative projects $469.3 million revenue and $75.9 million earnings by 2028.

Uncover how Vericel's forecasts yield a $53.88 fair value, a 58% upside to its current price.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community span a very wide range, from about US$0.66 to roughly US$53.88 per share, underscoring how differently investors can view Vericel. When you set those views against the current focus on scaling MACI manufacturing capacity, it becomes even more important to examine several alternative opinions on how execution and reimbursement risks could affect future performance.

Explore 2 other fair value estimates on Vericel - why the stock might be worth as much as 58% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Vericel research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Vericel research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Vericel's overall financial health at a glance.

Looking For Alternative Opportunities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.